Breathe Easy

Contact Information:

Ryan Thomas, MD:
@MSUPedsPulm

Robert Quinn, PhD:
@Quinn_Labs

ATS Peds:
@ATSPeds

Selected Relevant References:

Lindsay Caverly:

• Caverly LJ et al. Measures of Cystic Fibrosis Airway Microbiota During Periods of Clinical Stability. Ann Am Thorac Soc. 2019 Dec;16(12):1534-1542.
• Caverly LJ, Zhao J, LiPuma JJ. Cystic fibrosis lung microbiome: Opportunities to reconsider management of airway infection. Pediatr Pulmonol . 2015 Oct;50 Suppl 40:S31-8.
• Caverly LJ, Huang YJ, Sze MA. Past, Present, and Future Research on the Lung Microbiome in Inflammatory Airway Disease. Chest . 2019 Aug;156(2):376-382.
• Caverly LJ, LiPuma JJ. Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice. Expert Rev Respir Med. 2018 Oct;12(10):857-865.
• Carmody et al. Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis. PLoS One. 2018 Mar 9;13(3):e0194060.

Robert Quinn:

• Quinn RA et al. Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome. ISME J. 2016 Jun; 10(6): 1483–1498.
• Quinn RA et al. A Winogradsky-based culture system shows an association between microbial fermentation and cystic fibrosis exacerbation. The ISME Journal volume 9, pages1024–1038. ISME J. 2015 Mar 17;9(4):1024-38.
• Quinn RA et al. Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease. PeerJ. 2016 Aug 11;4:e2174.
• Raghunashi R et al. High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy. mSystems. 2020 Jun 23;5(3):e00292-20.
• Quinn RA et al. Ecological networking of cystic fibrosis lung infections. NPJ Biofilms Microbiomes. 2016 Dec 2;2:4.

Other Referenced Works:

• Muhlebach MS et al. Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children. PLoS Pathog. 2018 Jan 18;14(1):e1006798.
• Sly PD et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180: pp. 146-152
• JM Flynn et al. Disruption of Cross-Feeding Inhibits Pathogen Growth in the Sputa of Patients with Cystic Fibrosis.
• Muhlebach MS et al. Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study. Eur Respir J. 2018 Jul 11;52(1):1800242. mSphere. 2020 Apr 29;5(2):e00343-20.
• Pittman JE et al. Association of Antibiotics, Airway Microbiome, and Inflammation in Infants with Cystic Fibrosis. Ann Am Thorac Soc. 2017 Oct;14(10):1548-1555.
• Nelso MT et al. Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome. Thorax. 2020 Jul 6
• Cowley SC et al. Pediatric Cystic Fibrosis Sputum Can Be Chemically Dynamic, Anoxic, and Extremely Reduced Due to Hydrogen Sulfide Formation. mBio. 2015 Jul 28;6(4):e00767.
• Heltshe SL et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2015 Mar 1;60(5):703-12.
• Singh SB. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor. Pediatr Pulmonol. 2019 Aug;54(8):1200-1208.
• Hisert KB et al. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1617-1628.

A discussion of vaccine information, hesitancy and uptake among multiple populations and how we can improve uptake in our daily practices

Show References

1. McElfish PA, Willis DE, Shah SK, Bryant-Moore K, Rojo MO, Selig JP. Sociodemographic Determinants of COVID-19 Vaccine Hesitancy, Fear of Infection, and Protection Self-Efficacy. J Prim Care Community Health. Jan-Dec 2021;12:21501327211040746. doi:10.1177/21501327211040746
2. MacDonald NE, Hesitancy SWGoV. Vaccine hesitancy: Definition, scope and determinants. Vaccine. Aug 14 2015;33(34):4161-4. doi:10.1016/j.vaccine.2015.04.036
3. Nguyen LH, Joshi AD, Drew DA, et al. Racial and ethnic differences in COVID-19 vaccine hesitancy and uptake. medRxiv. Feb 28 2021;doi:10.1101/2021.02.25.21252402
4. Wong LP, Alias H, Danaee M, et al. COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries. Infect Dis Poverty. Oct 7 2021;10(1):122. doi:10.1186/s40249-021-00900-w
5. Jacobson RM, St Sauver JL, Finney Rutten LJ. Vaccine Hesitancy. Mayo Clin Proc. Nov 2015;90(11):1562-8. doi:10.1016/j.mayocp.2015.09.006
6. S. B. Omer, D. A. Salmon, W. A. Orenstein, M. P. deHart and N. Halsey. Vaccine Refusal, Mandatory Immunization, and the Risks of Vaccine-Preventable Diseases. NEJM 2009 Vol. 360 Issue 19 Pages 1981-1988
7. Lila J. Finney Rutten, Xuan Zhu, Aaron L. Leppin, Jennifer L. Ridgeway, Melanie D. Swift, Joan M. Griffin, Jennifer L. St Sauver, Abinash Virk, Robert M. Jacobson. Evidence-Based Strategies for Clinical Organizations to Address COVID-19 Vaccine Hesitancy. Mayo Clinic Proceedings. Volume 96, Issue 3. 2021. Pages 699-707.
8. Raymond John D Vergara, Philip Joseph D Sarmiento, James Darwin N Lagman, Building public trust: a response to COVID-19 vaccine hesitancy predicament, Journal of Public Health, Volume 43, Issue 2, June 2021, Pages e291–e292, https://doi.org/10.1093/pubmed/fdaa282
9. Corbie-Smith G. Vaccine Hesitancy Is a Scapegoat for Structural Racism. JAMA Health Forum. 2021;2(3):e210434. doi:10.1001/jamahealthforum.2021.0434
10. The 'successful failures' of Apollo 13 and Covid-19 vaccination - STAT (statnews.com)

Resources mentioned during this podcast

Apps

• Insight Timer
• Headspace
• 10% Happier

Websites

• UCSD Center for Mindfulness
• Mindful.org
• Mindful Healthcare Collective

Guest

Ni-Cheng Liang, MD

Host

Nina Bracken, MSN, ACNP-BC

More Information: ATS COVID-19 Resource Center

This podcast features Dr. Todd Miano is a critical care pharmacist and renowned pharmacoepidemiologist who has dedicated his career to improving the safety and effectiveness of acutely ill patients. Dr. Miano has been a pioneer in research involving drug interaction effects and causality. His work has identified both interactions that may have been overhyped and ones that clinicians may not be as familiar with but should be.